Elevated TSH: Work-Up and Initial Treatment
Immediate Confirmation Testing
Repeat TSH and measure free T4 after 3–6 weeks before initiating any treatment, as 30–60% of elevated TSH values normalize spontaneously. 1 This single step prevents unnecessary lifelong therapy in patients with transient thyroid dysfunction. The TSH test demonstrates 98% sensitivity and 92% specificity for detecting thyroid dysfunction 1, making it highly reliable once confirmed on repeat testing.
Measure anti-TPO antibodies during the confirmatory visit to identify autoimmune thyroiditis (Hashimoto's disease), which predicts a 4.3% annual progression risk to overt hypothyroidism versus 2.6% in antibody-negative individuals 1. This information directly influences treatment decisions for borderline TSH elevations.
Critical Safety Assessment Before Treatment
Before starting levothyroxine in any patient, measure morning (8 AM) cortisol and ACTH to exclude adrenal insufficiency, because initiating thyroid hormone without adequate cortisol can trigger life-threatening adrenal crisis. 1, 2 This is non-negotiable in patients with suspected central hypothyroidism, autoimmune disease, or those on immune checkpoint inhibitors. If adrenal insufficiency is confirmed, start hydrocortisone (20 mg morning, 10 mg afternoon) at least one week before levothyroxine 1.
Screen for recent iodine exposure (CT contrast), acute illness, or medications (lithium, amiodarone, immune checkpoint inhibitors) that can transiently elevate TSH 1. Testing during these periods produces misleading results.
Treatment Algorithm Based on TSH Level
TSH >10 mIU/L with Normal Free T4
Initiate levothyroxine immediately regardless of symptoms, as this threshold carries approximately 5% annual risk of progression to overt hypothyroidism and is associated with cardiac dysfunction and adverse lipid profiles. 1 The evidence supporting treatment at this level is rated "fair quality" by expert panels 1.
Starting dose:
- Patients <70 years without cardiac disease: 1.6 mcg/kg/day (full replacement dose) 1
- Patients >70 years OR with cardiac disease/multiple comorbidities: 25–50 mcg/day, titrate by 12.5–25 mcg every 6–8 weeks 1
The conservative approach in elderly or cardiac patients prevents unmasking coronary ischemia or precipitating arrhythmias 1.
TSH 4.5–10 mIU/L with Normal Free T4 (Subclinical Hypothyroidism)
Routine levothyroxine treatment is NOT recommended for asymptomatic patients in this range, as randomized trials show no symptomatic benefit. 1 Instead, monitor TSH every 6–12 months 1.
Consider treatment in these specific situations:
- Pregnant women or planning pregnancy: Treat any TSH elevation, targeting TSH <2.5 mIU/L in first trimester 1
- Positive anti-TPO antibodies: Higher progression risk justifies treatment 1
- Symptomatic patients: Offer 3–4 month trial with clear evaluation of benefit 1
- Patients with goiter or infertility: Treatment may be beneficial 1
TSH >10 mIU/L with Low Free T4 (Overt Hypothyroidism)
Start levothyroxine without delay to prevent cardiovascular dysfunction, adverse lipid profiles, and quality of life deterioration. 1 Use the same dosing strategy as above based on age and cardiac status.
Special Population: Central Hypothyroidism
If free T4 is low with normal or low TSH, suspect pituitary or hypothalamic disease 2. This represents a completely different diagnostic pathway:
- Rule out and treat adrenal insufficiency FIRST (measure morning cortisol and ACTH) 2
- Evaluate for other pituitary hormone deficiencies (approximately 50% have panhypopituitarism) 2
- Start levothyroxine only after cortisol replacement is established 2
- Monitor free T4 levels (NOT TSH) to guide dosing, targeting upper half of reference range 2, 3
Monitoring Protocol
Recheck TSH and free T4 every 6–8 weeks after any dose adjustment until target TSH of 0.5–4.5 mIU/L is achieved. 1 This interval is required for levothyroxine to reach steady state. Free T4 helps interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize 1.
Once stable, repeat TSH every 6–12 months or sooner if symptoms change 1.
Critical Pitfalls to Avoid
Never treat based on a single elevated TSH value—30–60% normalize spontaneously, representing transient thyroiditis or recovery from acute illness 1.
Approximately 25% of patients on levothyroxine are unintentionally overtreated with suppressed TSH (<0.1 mIU/L), which increases risk of atrial fibrillation (3–5 fold), osteoporosis, fractures, and cardiovascular mortality. 1 If TSH drops below 0.1 mIU/L, reduce levothyroxine by 25–50 mcg immediately 1. For TSH 0.1–0.45 mIU/L, reduce by 12.5–25 mcg, particularly in elderly or cardiac patients 1.
Never start thyroid hormone before ruling out adrenal insufficiency in suspected central hypothyroidism—this can precipitate adrenal crisis 1, 2.
Do not adjust doses more frequently than every 6–8 weeks—changing doses before steady state leads to inappropriate adjustments 1.
Patients on Immune Checkpoint Inhibitors
Thyroid dysfunction occurs in 6–9% with anti-PD-1/PD-L1 therapy and 16–20% with combination immunotherapy 1. Monitor TSH every 4–6 weeks for the first 3 months, then every second cycle thereafter. 1 Consider treatment even for subclinical hypothyroidism if fatigue or other symptoms are present 1. Immunotherapy can continue in most cases, as thyroid dysfunction rarely requires treatment interruption 1.
Long-Term Safety
When properly dosed (TSH 0.5–4.5 mIU/L), levothyroxine is safe for lifelong use 1. The primary risks stem from overtreatment, not from the medication itself at replacement doses 1. Regular monitoring prevents the complications of TSH suppression, which include atrial fibrillation, bone loss, and increased cardiovascular mortality, especially in patients over 60 years 1.